Total debt has fallen from $5.0M in 2024Q2 to $145.0K in 2026Q3, yet cash of $14.2M against a $170.2M net loss in 2026Q1 suggests the balance sheet relies on periodic equity raises and offers a thin cash cushion.
Faeth Therapeutics, Inc. (FTH) balance sheet — 8-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 |
|---|
| Total Current Assets | 177.84M | 21.51M | 41.93M | 67.25M | 108.59M | 148.54M | 20.08M | 502K | 1.28M |
| Cash & Short-Term Investments | 174.79M | 21.18M | 41.34M | 65.76M | 107.12M | 147.62M | 16.6M | 251K | 653K |
| Cash Only | 14.18M | 8.67M | 9.99M | 13.01M | 17.8M | 7.16M | 16.6M | 251K | 653K |
| Short-Term Investments | 160.62M | 12.52M | 31.34M | 52.75M | 89.32M | 140.46M | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 3.05M | 92K | 120K | 325K | 344K | 374K | 2.1M | 0 | 123K |
| Total Non-Current Assets | 1.11M | 1.4M | 3.43M | 7.12M | 9.79M | 4.68M | 1.35M | 715K | 570K |
| Property, Plant & Equipment | 127K | 1.38M | 3.38M | 7.04M | 9.72M | 4.64M | 1.27M | 268K | 123K |
| Fixed Asset Turnover | 0.00x | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 981K | 18K | 48K | 86K | 63K | 39K | 86K | 447K | 447K |
| Total Assets | 178.95M | 22.9M | 45.36M | 74.37M | 118.38M | 153.22M | 21.43M | 1.22M | 1.85M |
| Asset Turnover | 0.00x | - | - | - | - | - | - | - | - |
| Asset Growth % | 1431.35% | -49.51% | -39.01% | -37.17% | -22.74% | 615.07% | 1660.72% | -34.22% | - |
| Total Current Liabilities | 11.03M | 4.25M | 5.45M | 5.64M | 9.07M | 4.89M | 4.83M | 21.71M | 2.66M |
| Accounts Payable | 2.99M | 689K | 244K | 1.69M | 4.47M | 2.46M | 3.88M | 3.45M | 1.11M |
| Days Payables Outstanding | 6.34 | - | 161.63 | 1.08K | 903.01 | 1.31K | 6.78K | 17.25K | 9.19K |
| Short-Term Debt | 145K | 0 | 0 | 0 | 0 | 0 | 0 | 16.05M | 696K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.08M | 652K |
| Other Current Liabilities | 7.9M | 1.4M | 2.01M | 0 | 0 | 0 | 0 | -1.96M | 207K |
| Current Ratio | 16.12x | 5.06x | 7.70x | 11.92x | 11.98x | 30.38x | 4.16x | 0.02x | 0.48x |
| Quick Ratio | 16.12x | 5.06x | 7.70x | 11.92x | 11.98x | 30.38x | 4.16x | 0.02x | 0.48x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 53K | 59K | 1.53M | 3.84M | 5.9M | 1.82M | 705K | 48.16M | 52.67M |
| Long-Term Debt | 0 | 59K | 0 | 0 | 0 | 0 | 567K | 0 | 4.05M |
| Capital Lease Obligations | 0 | 0 | 1.53M | 3.77M | 5.9M | 1.67M | 86K | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 53K | 0 | 0 | 67K | 0 | 149K | 52K | 48.16M | 48.62M |
| Total Liabilities | 11.09M | 4.31M | 6.97M | 9.48M | 14.97M | 6.71M | 5.54M | 69.88M | 55.33M |
| Total Debt | 145K | 1.51M | 3.85M | 6.21M | 8.03M | 2.35M | 685K | 16.05M | 4.75M |
| Net Debt | -14.04M | -7.16M | -6.15M | -6.8M | -9.76M | -4.8M | -15.91M | 15.8M | 4.09M |
| Debt / Equity | 0.00x | 0.08x | 0.10x | 0.10x | 0.08x | 0.02x | 0.04x | - | - |
| Debt / EBITDA | -0.00x | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.06x | - | - | - | - | - | - | - | - |
| Interest Coverage | -71014.33x | -657.91x | -334.08x | -256.69x | -220.86x | -53.92x | -10.90x | -6.42x | -38.87x |
| Total Equity | 167.86M | 18.59M | 38.39M | 64.89M | 103.41M | 146.51M | 15.89M | -68.66M | -53.48M |
| Equity Growth % | 1608.99% | -51.57% | -40.85% | -37.24% | -29.42% | 821.87% | 123.15% | -28.39% | - |
| Book Value per Share | 6.50 | 14.75 | 30.57 | 46.43 | 67.36 | 105.74 | 10.39 | -46.83 | -36.47 |
| Total Shareholders' Equity | 167.86M | 18.59M | 38.39M | 64.89M | 103.41M | 146.51M | 15.89M | -68.66M | -53.48M |
| Common Stock | 3K | 0 | 3K | 3K | 3K | 3K | 0 | 2K | 2K |
| Retained Earnings | -489.78M | -283.14M | -262.05M | -231.9M | -197.79M | -149.21M | -112.41M | -92.31M | -75.57M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -153K | 1K | -13K | -209K | -1M | -333K | 0 | -2K | -314K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying FTH stock.
As of 2025, Faeth Therapeutics, Inc. (FTH) had total assets of $22.9M including $21.5M in current assets.
Faeth Therapeutics, Inc. (FTH) carries total debt of $1.5M, offset by $21.2M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Faeth Therapeutics, Inc. (FTH) has total shareholders' equity (book value) of $18.6M ($14.75 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Faeth Therapeutics, Inc. (FTH) reported a current ratio of 5.06x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Thin cash cushion post-2026Q1
Metrics are mathematically derived from official filings.
Asset Base Swelled Then Reversed
Based on reported figures, FTH's total assets climbed from $59.8M in 2024Q2 to $205.4M in 2026Q1 before falling back to $178.9M in 2026Q3, a pattern that appears driven by a large cash inflow followed by steady consumption.
The 2026Q1 spike was driven almost entirely by cash rising to $152.3M, which suggests a financing or capital event rather than operating strength. Cash then fell to $14.2M by 2026Q3, indicating that the balance sheet is now far more fragile than the headline asset figure implies. Investors should monitor whether the remaining asset base can sustain operations without further capital.
Current Ratio Masks Thin Cash Cushion
According to reported financial statements, FTH's current ratio of 16.12 in 2026Q3 looks robust, yet cash of $14.2M against a quarterly net loss of $170.2M in 2026Q1 suggests limited buffer against continued burn.
The elevated current ratio largely reflects a small liability base of $11.1M rather than abundant liquid resources, so it overstates true resilience. With operating cash flow negative in every quarter and cash falling from $152.3M to $14.2M within two quarters, the implied runway appears short. This warrants close attention to how quickly remaining cash is being consumed.
Deepening Accumulated Deficit Drives Equity
As reported in balance sheet data, FTH's retained earnings deficit widened from -$247.0M in 2024Q2 to -$489.8M in 2026Q3, while equity still stands at $167.9M due to periodic capital raises.
The accumulated deficit has grown every quarter, indicating persistent losses that have been absorbed by equity financing rather than earnings. Equity of $167.9M is therefore sustained by paid-in capital that appears to be the main source of solvency. The quality of this equity depends on continued access to capital markets, which the reported figures do not guarantee.
Stock Compensation Inflates Equity Base
Based on reported stock-based compensation rising to $12.9M in 2026Q1, a meaningful share of operating cost is settled in equity, which may dilute existing holders and flatter the apparent cash position.
Equity-settled compensation adds to paid-in capital without consuming cash, so a healthy-looking equity figure may partly reflect non-cash awards rather than invested capital. This may indicate dilution that is not visible in the balance sheet totals alone. Investors should assess share count growth alongside the equity figure before treating it as a measure of underlying strength.
Minimal Debt Limits Leverage Risk
According to reported figures, FTH's total debt fell from $5.0M in 2024Q2 to $145.0K in 2026Q3, leaving a debt-to-equity ratio near zero and limiting leverage as a source of balance sheet pressure.
Debt has been run down steadily, which suggests the company is not relying on borrowing to fund its operations. The near-zero leverage removes refinancing risk, though it also means the company depends on equity financing for survival. The balance sheet risk is therefore one of cash exhaustion rather than debt service.